EyePoint (EYPT) Cost of Revenue (2019 - 2026)
EyePoint (EYPT) reported Cost of Revenue of $528000.0 for Q1 2026, down 34.41% on a YoY basis from $805000.0 in Q1 2025, and up 40.8% sequentially from $375000.0 in Q4 2025.
EyePoint (EYPT) Cost of Revenue (2019 - 2026) Analysis & Trends
EyePoint (EYPT) has 8 years of Cost of Revenue data on file, last reported at $528000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cost of Revenue fell 34.41% year-over-year to $528000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 52.39% YoY), and the FY2025 full-year result was $2.1 million, down 44.34% from the prior year.
- Cost of Revenue rose to $528000.0 in Q1 2026, from $375000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $3.4 million in Q4 2022 to a low of $165000.0 in Q2 2025.
- A 5-year average of $1.1 million and a median of $816000.0 in 2024 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue gained 27.84% in 2022 and slumped 88.22% in 2025, its largest moves.
- Tracing EYPT's Cost of Revenue over 5 years: stood at $3.4 million in 2022, then plunged by 70.73% to $998000.0 in 2023, then retreated by 18.24% to $816000.0 in 2024, then plunged by 54.04% to $375000.0 in 2025, then surged by 40.8% to $528000.0 in 2026.
- Business Quant data shows EYPT's Cost of Revenue at $528000.0 in Q1 2026, $375000.0 in Q4 2025, and $721000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 | 528,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 528,000.00 |
| Mar 31, 2026 | 528,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 759,000.00 |
| Mar 31, 2024 | 759,000.00 |
| Dec 31, 2023 | 998,000.00 |
| Dec 31, 2023 | 998,000.00 |